Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma
Phase 2
Completed
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Drug: GPX-150 for Injection
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- Gem Pharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT02267083
- Locations
- ๐บ๐ธ
Washington University School of Medicine, Saint Louis, Missouri, United States
๐บ๐ธPenn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
๐บ๐ธUniversity of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
Safety Study of GPX-150 in Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumors - Phase 1 Population
- Interventions
- Drug: GPX-150 for Injection
- First Posted Date
- 2008-07-04
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Gem Pharmaceuticals
- Target Recruit Count
- 27
- Registration Number
- NCT00710125
- Locations
- ๐บ๐ธ
University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
Study of GPX-100 in the Treatment of Metastatic Breast Cancer
Phase 2
Terminated
- Conditions
- Breast CancerMetastasis
- First Posted Date
- 2005-07-26
- Last Posted Date
- 2007-01-09
- Lead Sponsor
- Gem Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT00123877
- Locations
- ๐บ๐ธ
Huntsman Cancer Center, University of Utah, Salt Lake City, Utah, United States
๐ง๐ฌSofia Cancer Center, Sofia, Bulgaria
๐ง๐ฌUniversity Hospital Queen Joanna, Sofia, Bulgaria
GPX-100 in Treating Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2013-04-23
- Lead Sponsor
- Gem Pharmaceuticals
- Registration Number
- NCT00003403
- Locations
- ๐บ๐ธ
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
๐บ๐ธHuntsman Cancer Institute, Salt Lake City, Utah, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath